Immunex Corporation v. Sandoz Inc., No. 20-1037 (Fed. Cir. July 1, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Patent owner Hoffmann-La Roche Inc. (“Roche”), its ex- clusive licensee Immunex Corp., and exclusive sublicensee Amgen Manufacturing, Ltd., initiated this patent infringe- ment suit pursuant to the Biologics Price Competition and Innovation Act (“BPCIA”). 1 Sandoz, Inc., Sandoz 1 Immunex Corp. and Amgen Manufacturing, Ltd . are collectively referred to as “Immunex.” Although Roche joined the district court litigation, it did not enter an ap- pearance in this appeal. IMMUNEX CORP. v. SANDOZ, INC.